BLUENERGIES LTD (BLU.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:BLU - CA0959221007 - Common Stock
BLU.CA Key Statistics, Chart & Performance
The current stock price of BLU.CA is 1.1 CAD. In the past month the price increased by 22.22%.
BLU.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 522.71M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 416.39M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 181.02M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 76.74M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.86 | 48.06M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 31.97M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.42M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 11.90M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.03M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About BLU.CA
Company Profile
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
Company Info
BLUENERGIES LTD
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7 CA
CEO: Roberto Bellini
Employees: 74
Phone: 14506804500.0
BLUENERGIES LTD / BLU.CA FAQ
Can you describe the business of BLUENERGIES LTD?
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
What is the stock price of BLUENERGIES LTD today?
The current stock price of BLU.CA is 1.1 CAD. The price decreased by -12% in the last trading session.
What is the dividend status of BLUENERGIES LTD?
BLU.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BLU stock?
BLU.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the market capitalization of BLU stock?
BLUENERGIES LTD (BLU.CA) has a market capitalization of 139.48M CAD. This makes BLU.CA a Micro Cap stock.
BLU.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLU.CA.
BLU.CA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |